mRNA transfected dendritic cell cancer immunotherapy (Regen BioPharma)

N/A

Report date: 2025/03/20 15:52:03

Base Information

Drug NamemRNA transfected dendritic cell cancer immunotherapy (Regen BioPharma)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineCell and gene therapy > Cell therapy
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegen Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegen Biopharma IncOncology Pharma Inc
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A